Nuvectis Pharma, Inc.
No SEC Form 4 filings for $NVCT in the last 30 days.
Nuvectis Pharma (NVCT) reported a wider Q2 2026 net loss of $7.02 million, or $0.30 per share, versus $6.33 million a year earlier. Operating loss rose to $7.20 million. R&D costs increased to $4.68 million from $3.61 million, while G&A fell to $2.51 million from $2.98 million. NVCT shares were down 7.06% at $20.08.
Nuvectis Pharma (NASDAQ: NVCT) reported Q2 2026 results and said it completed in-licensing ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco. Ciprocopan received China marketing approval in July 2026 for PNH patients not previously treated with complement inhibitors. The company raised $115M gross in a July follow-on offering, extending cash runway into 1H 2029. Cash was $22.2M at June 30, 2026; net loss was $7.0M.
Nuvectis Pharma, Inc. (NVCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622125d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights · Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical G
Over the past 7 days, alphai's AI scored 3 news stories mentioning NVCT (Nuvectis Pharma, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 1 bearish.
Recent NVCT coverage spans earnings, corporate actions and financial news.
The quarter shows cost pressure from higher R&D, offset partly by lower G&A, likely reinforcing a cash-burn and runway risk premium for NVCT.
China approval for ciprocopan and a $115M follow-on offering extend runway while U.S. IND/marketing application work ramps.
The filing combines a financing extension (runway into 1H 2029) with a new commercial milestone in China, while outlining upcoming FDA IND steps for US development.
Deal plus Phase 3 efficacy data creates a clear late-2026 to early-2027 China catalyst for NVCT’s lead rare-disease asset.
Dilutive discounted equity issuance is pressuring near-term valuation and sentiment, with follow-through risk until deal absorption.
alphai scores every news story that mentions NVCT with an AI model for sentiment and relevance, and aggregates insider trades from Nuvectis Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nuvectis Pharma (NVCT) reported a wider Q2 2026 net loss of $7.02 million, or $0.30 per share, versus $6.33 million a year earlier. Operating loss rose to $7.20 million. R&D costs increased to $4.68 million from $3.61 million, while G&A fell to $2.51 million from $2.98 million. NVCT shares were down 7.06% at $20.08.
2 min readNuvectis Pharma (NASDAQ: NVCT) reported Q2 2026 results and said it completed in-licensing ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco. Ciprocopan received China marketing approval in July 2026 for PNH patients not previously treated with complement inhibitors. The company raised $115M gross in a July follow-on offering, extending cash runway into 1H 2029. Cash was $22.2M at June 30, 2026; net loss was $7.0M.
6 min readNuvectis Pharma, Inc. (NVCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622125d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights · Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical G
5 min readNuvectis Pharma (NVCT) said it licensed worldwide rights outside China to NXP100 and NXP200 from Haisco Pharmaceutical Group for $40M upfront plus up to $1.42B in milestones. NVCT cites Phase 3 results for NXP100 in PNH versus eculizumab: 59.5% vs 8.3% transfusion-free normal hemoglobin. Two China NMPA applications are under review, with decisions expected late 2026 to early 2027.
5 min readNuvectis Pharma (NASDAQ:NVCT) priced a $100 million public discounted stock offering at $20.00 per share, about 30% below Monday’s $28.53 close. The company will issue 5,000,000 shares and granted underwriters a 30-day option for up to 750,000 more shares. Shares fell ~25% premarket; closing expected around July 1, 2026.
3 min readMosseri Marlio Charles purchased 50,000 indirectly-held shares of Nuvectis Pharma, Inc. (NVCT) at $18.32 ($0.92M total) on 2026-06-30.
2 min readBENTSUR RON (Chairman & CEO) purchased 12,500 shares of Nuvectis Pharma, Inc. (NVCT) at $20.00 ($0.25M total) on 2026-06-30.
2 min readNuvectis Pharma, Inc. (NVCT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 tm2619346d1_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 Execution Version 5,000,000 Shares of Common Stock Nuvectis Pharma, Inc. UNDERWRITING AGREEMENT June 29, 2026 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed on Schedule IA hereto c/o Cantor Fitzg
3 min readNuvectis Pharma, Inc. (NVCT) shares fell about 30% on Tuesday. The drop follows the company’s announcement of a 5 million-share offering priced at $20.00 per share, targeting about $100 million in gross proceeds, according to the report. NVCT was around $19.90, down from a prior close of $28.53 on Nasdaq.
2 min readHaisco and Nuvectis signed a licensing deal covering Haisco’s drug candidates HSK42360 and HSK39297. Nuvectis received worldwide rights outside specified Asian territories to develop, manufacture and commercialise. Haisco will get $40m upfront/near-term, plus milestones up to $1.4bn and tiered royalties. Milestones may include cash and common stock (equity capped <40%); financing conditions apply.
3 min read
